Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-12-06
2008-09-02
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S320100, C435S455000, C514S001000, C536S023100
Reexamination Certificate
active
07419964
ABSTRACT:
A composition for treatment of HSV-related pathologies including an expression vector for altering expression of a target sequence in an HSV-infected cell by production of single-stranded cDNA (ssDNA) in the cell in vivo suspended for topical application to an affected site in a suitable delivery vehicle. The expression vector is comprised of a cassette comprising a sequence of interest, an inverted tandem repeat, and a primer binding site 3′ to the inverted tandem repeat, and a reverse transcriptase/RNAse H coding gene, and is transfected into the infected cells for inhibition of HSV replication. The resulting ssDNA binds to the target sequence to alter expression of the target sequence for such purposes as gene activation or inactivation using duplex or triplex binding of nucleic acids, site-directed mutagenesis, interruption of cellular function by binding to specific cellular proteins, or interfering with RNA splicing functions.
REFERENCES:
patent: 5436141 (1995-07-01), Miyata et al.
patent: 5503978 (1996-04-01), Schneider et al.
patent: 5795721 (1998-08-01), Rabin et al.
patent: 5837289 (1998-11-01), Grasela et al.
patent: 6057367 (2000-05-01), Stamler et al.
patent: 6190866 (2001-02-01), Nielsen et al.
patent: A2-0530112 (1993-03-01), None
patent: A2-0532380 (1993-03-01), None
patent: A2-0562206 (1993-09-01), None
patent: WO-A-94/01550 (1994-01-01), None
patent: WO-A-94/13689 (1994-06-01), None
patent: WO-A-94/20639 (1994-09-01), None
patent: WO-A-94/23026 (1994-10-01), None
patent: WO-A-95/35369 (1995-12-01), None
patent: WO 00/22113 (2000-04-01), None
patent: WO 00/22114 (2000-04-01), None
patent: WO 01/25419 (2001-04-01), None
patent: WO 03/093424 (2003-11-01), None
Peracchi, A. et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Crooke, S. Antisense Research and Application, Chapter 1, pp. 1-50, Ed. by S. Crooke, Publ. by Springer-Verlag (1998).
Branch, A., Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Chirila, T. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Crooke, S., et al., Antisense Research and Application, Chapter 1, 1-50, Ed. by S. Crooke, Springer-Verlag, 1998.
Agrawal, S., et al.,Antisense therapeutics: is it as simple as complementary base recognition?, Molecular Medicine Today, 6:72-81, 2000.
Akhtar, S., et al.,The delivery of antisense therapeutics, Advanced Drug Delivery Reviews, 44:3-21, 2000.
Alexander, C., et al.,Bacterial lipopolysaccharides and innate immunity, J. of Endotoxin Research, 7(3): 167-202, 2001.
Angus, D., et al.,Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care, Crit Care Med., 29(7):1303-1310, 2001.
Beard, P., et al.,Herpes simplex virus immediate early infected-cell polypeptide 4 binds to DNA and promotes transcription, Proc. Natl. Acad. Sci., 83:4016-4020, 1986.
Bochud, P., et al.,Antibiotics in sepsis, Intensive Care Med., 27: S33-S48, 2001.
Branch, Andrea,A good antisense molecule is hard to find, Trends in Biochem. Sci., 23:45-50, 1998.
Breaker, R.,Catalytic DNA: in training and seeking employment, Nature Biotechnology, 17:422-423, 1999.
Breaker, R.R. and Joyce, G.F.,A DNA enzyme that cleaves RNA, Chemistry & Biology, 1:223-229, 1994.
Breaker, R.R. and Joyce, G.F.,A DNA enzyme with Mg(2+)-dependent RNA phosphodiesterase activity, Chemistry & Biology, 2: 655-660, 1995.
Breaker, R.R.,Making Catalytic DNAs, Science, 290: 2095-2096, 2000.
Breaker, R.R., In VitroSelection of Catalytic Polynucleotides, Chem. Rev., 97: 371-90, 1997.
Calandra, T.,Pathogenesis of Septic Shock: Implications for Prevention and Treatment, Journal of Chemotherapy, 13(1): 173-180, 2001.
Carmi, N., et al.,Cleaving DNA with DNA, PNAS, 95(5): 2233-2237, 1998.
Chen, et al, In VivoExpression of Single-Stranded DNA in Mammalian Cells with DNA Enzyme Sequences Targeted to c-raf, Antisense & Nuc. Acid Drug Development, 10(6): 415-422, Dec. 2000.
Chen, Y.,A novel single-stranded DNA expression vector, Expert Opin. Biol. Ther., 2(7): 735-740, 2002.
Chen, Y., et al.,Novel Intracellular Single-Stranded DNA Expression System: Production of c-raf RNA-cleaving DNA Enzyme, Gene Therapy 2001: A Gene Odyssey, Keystone Symposia, Snowbird, Utah, Jan. 2001 (Abstract-1) -Assignee.
Chen, Y., et al.,Novel intracellular single-stranded DNA expression system: Production of c-raf RNA-cleaving DNA enzyme, Cancer Gene Therapy, vol. 8, Supp. 2, Abs. No. O-6, Dec. 2001 (Abstract-2) -Assignee.
Chirila, T., et al.,The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides, Biomaterials, 23:321-342, 2002.
Cohen, J.,The immunopathogenesis of sepsis, Nature, 420: 885-891, 2002.
Cohen, P.,A Marvel of Biochemical Engineering Means Cells Can Produce DNA Enzymes to Attack Cancer, New Scientist Oneline News, 1328 GMT, Jan. 9, 2001.
Cuenod, B. and Szostak, J.,A DNA metalloenzyme with DNA ligase activity, Nature, 375:611-614, 1995.
Dai, K. and Lutkenhaus, J.,ftsZ is an Essential Cell Division Gene in Escherichia coli, Journal of Bacteriology, 173 (11): 3500-3506, 1991.
Datta, H.J. and Glazer, P.M.,Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombination, Nucleic Acids Research, 29 (24): 5140-5147, 2001.
Deluca, N., et al.,Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4, Journal of Virology, 56 (2):558-570, 1985.
Dias, Nathalie and Stein, C.A.,Antisense Oligonucleotides: Basic Concepts and Mechanisms, Molecular Cancer Therapeutics, 1: 347-355, 2002.
Disney, G.H., et al.,The product of varicella-zoster virus gene 62 autoregulates its own promoter, Journal of General Virology, 71:2999-3003, 1990.
Emilsson et al.,Deoxyribozymes: New Activities and New Applications, Cellular and Molec Life Sci. 59: 596-607 (2002).
Faulhammer and Famulok, M.,Characterization and Divalent Metalion Dependence ofin vitroSelected Deoxyribozymes which Cleave DNA/ RNA Chimeric Oligonucleotides, Jour Molec Biol, 269: 188-203, 1997.
Galocha, B., et al.,The Active Site of ICP47, a Herpes Simplex Virus-encoded Inhibitor of the Major Histocompatibility complex(MHC)-encoded Peptide Transporter Associated with Antigen Processing(TAP),Maps to the NH2—terminal 35 Residues, J. Exp. Med., 185(9):1565-1572, 1997.
Inouye, S., et al.,Highly Specific Recognition of Primer RNA Structures for 2'-OH Priming Reaction by Bacterial Reverse Transcriptases, Journal of Biological Chemistry, 274 (44): 31236-31244, 1999.
Jugovic, P., et al.,Inhibition of Major Histocompatibility Complex Class I Antigen Presentation in Pig and Primate Cells by Herpes Simples Virus Type 1 and 2 ICP47, Journal of Virology, 72(6):5076-5084, 1998.
Lampson, B., et al.,The msDNAs of Bacteria, Prog. Nucleic Acid Res. Mol. Biol., 67: 65-91, 2001.
Lau, Q.C., et al.,Abrogation of c-RAF expression induces apoptosis in tumor cells, Oncogene, 16: 1899-1902, 1998.
Li, Y. and Breaker, R.,Phosphorylating DNA with DNA, Proc. Natl. Acad. Sci., 96:2746-2751, 1999.
Li, Y., et al.,Complete Nucleotide Sequence, Genome Organization, and Biological Properties of Human Immunodeficiency Virus Type 1in Vivo:Evidence for Limited Defectiveness and complementation, Journal of Virology, 66(11):6587-6600, 1992.
Mao, J.R., et al.,Gene regulation by antisense DNA producedin vivo, J. of Biol. Chem., 270(34): 19684-19687, 1995.
Matthews, J.T., et al.,The structure and function of the HSV DNA replication proteins: defining novel antiviral targets, Antiviral Research, 20:89-114, 1993.
McGeoch, D.J., et al.,Molecular Phylogeny of the Alphaherpesvirinae Subfamily and a Proposed Evolutionary Timescale, J. Mol. Biol., 238:9-22, 1994.
Mirochnitchenko, O., et al.,Production of single-stranded DNA in mammalian cells by means of a bacterial retron, J. of Biol. Chem., 269 (4):2380-2383, 1994.
Mohuczy, D., et al., Hypertension, Part 11:354-359, 1999 (first page only).
Moore, T, et al.,Experimental investigation and mathematical modeling of Pluronic F127 gel dissolution: drug r
Chen Yin
Skolnick Malcolm
Cytogenix, inc.
Ewell Cindee R.
Zara Jane
LandOfFree
Treatment of HSV-related pathologies using ssDNA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of HSV-related pathologies using ssDNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of HSV-related pathologies using ssDNA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3992610